Characterization of triple negative breast cancer gene expression profiles in Mexican patients.

IF 1.4 Q4 ONCOLOGY Molecular and clinical oncology Pub Date : 2023-01-01 DOI:10.3892/mco.2022.2601
Eric Ortiz Valdez, Claudia Rangel-Escareño, Juan Antonio Matus Santos, Rafael Vázquez Romo, Alberto Guijosa, Cynthia Villarreal-Garza, Oscar Arrieta, Rubén Rodríguez-Bautista, Claudia H Caro-Sánchez, Alette Ortega Gómez
{"title":"Characterization of triple negative breast cancer gene expression profiles in Mexican patients.","authors":"Eric Ortiz Valdez,&nbsp;Claudia Rangel-Escareño,&nbsp;Juan Antonio Matus Santos,&nbsp;Rafael Vázquez Romo,&nbsp;Alberto Guijosa,&nbsp;Cynthia Villarreal-Garza,&nbsp;Oscar Arrieta,&nbsp;Rubén Rodríguez-Bautista,&nbsp;Claudia H Caro-Sánchez,&nbsp;Alette Ortega Gómez","doi":"10.3892/mco.2022.2601","DOIUrl":null,"url":null,"abstract":"<p><p>Triple negative breast cancer (TNBC) is an aggressive type of cancer that accounts for ~23% of breast tumors in Mexico. In an attempt to understand in an improved way the behavior of TNBC, throughout the years, gene expression in these tumors has been studied. Lehman <i>et al</i> identified 6 subtypes of gene expression in TNBC with distinct characteristics. In the present study, it was aimed to assess clinical, pathological and prognostic characteristics of TNBC in a Mexican-based cohort. A total of 55 patients diagnosed with TNBC at Mexico's National Institute of Cancer (INCan) were included. Tumor needle biopsy samples were obtained and subjected to microarray analysis. Patients were thus classified into one of the 6 TNBC molecular subtypes. The prognostic, clinical and pathological information of patients was obtained, and differences across molecular subtypes were sought. Out of the 55 included patients, the following subtypes were identified: 9 basal-like-1, 11 basal-like-2 (BSL2), 16 immunomodulatory (IM), 12 mesenchymal, 6 androgen receptor-like and 1 mesenchymal stem-like. Mean follow-up time was 47.1 months. The IM molecular subtype had the best overall survival (OS) (median OS was not reached). BSL2 had the worst OS (15 months). A complete pathologic response to neoadjuvant chemotherapy was obtained more often in the IM subtype (P=0.032). No significant associations were found between any of the clinical or pathological characteristics and the TNBC molecular subtypes. The results obtained from the present study should be considered when seeking to implement a clinical-molecular model for TNBC patient care, particularly in Hispanic-based populations, as they have been frequently underrepresented in clinical studies assessing TNBC molecular subtypes.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 1","pages":"5"},"PeriodicalIF":1.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/56/mco-18-01-02601.PMC9808158.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mco.2022.2601","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Triple negative breast cancer (TNBC) is an aggressive type of cancer that accounts for ~23% of breast tumors in Mexico. In an attempt to understand in an improved way the behavior of TNBC, throughout the years, gene expression in these tumors has been studied. Lehman et al identified 6 subtypes of gene expression in TNBC with distinct characteristics. In the present study, it was aimed to assess clinical, pathological and prognostic characteristics of TNBC in a Mexican-based cohort. A total of 55 patients diagnosed with TNBC at Mexico's National Institute of Cancer (INCan) were included. Tumor needle biopsy samples were obtained and subjected to microarray analysis. Patients were thus classified into one of the 6 TNBC molecular subtypes. The prognostic, clinical and pathological information of patients was obtained, and differences across molecular subtypes were sought. Out of the 55 included patients, the following subtypes were identified: 9 basal-like-1, 11 basal-like-2 (BSL2), 16 immunomodulatory (IM), 12 mesenchymal, 6 androgen receptor-like and 1 mesenchymal stem-like. Mean follow-up time was 47.1 months. The IM molecular subtype had the best overall survival (OS) (median OS was not reached). BSL2 had the worst OS (15 months). A complete pathologic response to neoadjuvant chemotherapy was obtained more often in the IM subtype (P=0.032). No significant associations were found between any of the clinical or pathological characteristics and the TNBC molecular subtypes. The results obtained from the present study should be considered when seeking to implement a clinical-molecular model for TNBC patient care, particularly in Hispanic-based populations, as they have been frequently underrepresented in clinical studies assessing TNBC molecular subtypes.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
墨西哥患者三阴性乳腺癌基因表达谱的特征
三阴性乳腺癌(TNBC)是一种侵袭性癌症,约占墨西哥乳腺肿瘤的23%。为了更好地理解TNBC的行为,多年来,人们一直在研究这些肿瘤中的基因表达。Lehman等在TNBC中鉴定出6种具有不同特征的基因表达亚型。在本研究中,旨在评估墨西哥队列中TNBC的临床、病理和预后特征。共有55名在墨西哥国家癌症研究所(INCan)诊断为TNBC的患者被纳入研究。获得肿瘤穿刺活检样本并进行微阵列分析。因此,将患者分为6种TNBC分子亚型之一。获得患者的预后、临床和病理信息,并寻求不同分子亚型的差异。在55例纳入的患者中,鉴定出以下亚型:9例基底样-1,11例基底样-2 (BSL2), 16例免疫调节性(IM), 12例间充质,6例雄激素受体样和1例间充质茎样。平均随访时间47.1个月。IM分子亚型具有最佳的总生存期(OS)(未达到中位OS)。BSL2的OS最差(15个月)。IM亚型对新辅助化疗的完全病理反应更常见(P=0.032)。没有发现任何临床或病理特征与TNBC分子亚型之间的显著关联。在寻求实施TNBC患者护理的临床-分子模型时,应考虑本研究获得的结果,特别是在西班牙裔人群中,因为他们在评估TNBC分子亚型的临床研究中经常被低估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
108
期刊最新文献
Association between high‑density lipoproteins and prostate specific antigen: A cross‑sectional study from NHANES database. STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer. Correlation between BRCA1 expression and the advanced stage of triple‑negative breast cancer. PD‑1/PD‑L1 immune checkpoint in bone and soft tissue tumors (Review). Molecular mechanism and therapeutic strategies for embryonal tumors with multilayered rosettes in children (Review).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1